DBV Technologies (NASDAQ:DBVT) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report released on Wednesday morning. The brokerage issued a hold rating on the stock.

A number of other research firms also recently issued reports on DBVT. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price objective on shares of DBV Technologies in a report on Tuesday, September 24th. HC Wainwright lifted their target price on DBV Technologies from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, October 24th.

DBV Technologies Stock Performance

DBVT traded down $0.06 during mid-day trading on Wednesday, reaching $0.68. 112,471 shares of the stock were exchanged, compared to its average volume of 233,395. The stock has a market capitalization of $65.14 million, a PE ratio of -0.73 and a beta of 0.66. The company has a 50 day moving average price of $0.75 and a two-hundred day moving average price of $0.91. DBV Technologies has a 1 year low of $0.50 and a 1 year high of $2.14.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. lifted its holdings in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the quarter. DBV Technologies accounts for approximately 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.